THE SYMPTOM of vertigo, with or without accompanying nausea, is always both incapacitating and the cause of anxiety even when of brief duration. In recent years many compounds have been widely used to alleviate or prevent these symptoms, whether the etiology be due to natural causes (motion sickness) or the result of pathological lesions (Ménière's disease, vestibular neuronitis, central nervous system tumors, etc). Although numerous agents of widely different composition have unquestionable therapeutic value to varying degrees, they also produce other disturbing reactions. It is the object of this paper to describe the antivertigo effects of a new phenothiazine, thiethylperazine maleate.* This compound was chosen because it is free of the tranquilizing and other undesirable side effects so frequently found. Its action in the suppression of subjective nystagmus due to a variety of clinical conditions has been reported by other authors (Cox and Collins, Priver and Boros, Sparks, Browne, and
JOHNSON WH, IRELAND PE. The Control of Vertigo by Thiethylperazine. Arch Otolaryngol. 1965;82(3):261–266. doi:10.1001/archotol.1965.00760010263008
Customize your JAMA Network experience by selecting one or more topics from the list below.